Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2017

Open Access 01-12-2017 | Case report

Pulmonary toxicity after intraperitoneal mitomycin C: a case report of a rare complication of HIPEC

Authors: Melissa L. Abel, George Kokosis, Dan G. Blazer

Published in: World Journal of Surgical Oncology | Issue 1/2017

Login to get access

Abstract

Background

Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has become a common treatment approach for disseminated appendiceal neoplasms. Systemic absorption of intraperitoneal chemotherapeutics may lead to drug-induced toxicity, most commonly neutropenia. Mitomycin C has been the most commonly used chemotherapeutic in HIPEC for the past several decades.

Case presentation

Here, we describe a rare pulmonary complication secondary to intraperitoneal administration of mitomycin C.

Conclusions

While rare, intraperitoneal mitomycin C has the potential to cause serious pulmonary toxicity that should be considered with administration. To our knowledge, this report represents only the second case described in the literature.
Literature
1.
go back to reference Lambert LA. Looking up: recent advances in understanding and treating peritoneal carcinomatosis. CA Cancer J Clin. 2015;65(4):284–98.CrossRefPubMed Lambert LA. Looking up: recent advances in understanding and treating peritoneal carcinomatosis. CA Cancer J Clin. 2015;65(4):284–98.CrossRefPubMed
2.
go back to reference Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221(2):124–32.CrossRefPubMedPubMedCentral Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221(2):124–32.CrossRefPubMedPubMedCentral
3.
go back to reference Gonzalez-Moreno S. Peritoneal Surface Oncology: a progress report. Eur J Surg Oncol. 2006;32(6):593–6.CrossRefPubMed Gonzalez-Moreno S. Peritoneal Surface Oncology: a progress report. Eur J Surg Oncol. 2006;32(6):593–6.CrossRefPubMed
4.
go back to reference Stephens AD, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999;6(8):790–6.CrossRefPubMed Stephens AD, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999;6(8):790–6.CrossRefPubMed
5.
go back to reference Stewart JH, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol. 2006;13(5):624–34.CrossRefPubMed Stewart JH, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol. 2006;13(5):624–34.CrossRefPubMed
6.
go back to reference Yan TD, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007;14(10):2702–13.CrossRefPubMed Yan TD, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007;14(10):2702–13.CrossRefPubMed
7.
go back to reference Katz MH, Barone RM. The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies. Surg Oncol Clin N Am. 2003;12(3):673–88.CrossRefPubMed Katz MH, Barone RM. The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies. Surg Oncol Clin N Am. 2003;12(3):673–88.CrossRefPubMed
8.
go back to reference Kuzuya T, et al. Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. J Pharm Pharmacol. 1994;46(8):685–9.CrossRefPubMed Kuzuya T, et al. Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. J Pharm Pharmacol. 1994;46(8):685–9.CrossRefPubMed
9.
go back to reference Lambert LA, et al. Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol. 2009;16(8):2181–7.CrossRefPubMedPubMedCentral Lambert LA, et al. Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol. 2009;16(8):2181–7.CrossRefPubMedPubMedCentral
10.
go back to reference Kemmel V, et al. Mitomycin C pharmacokinetics as predictor of severe neutropenia in hyperthermic intraperitoneal therapy. Ann Surg Oncol. 2015;22 Suppl 3:873–9.CrossRef Kemmel V, et al. Mitomycin C pharmacokinetics as predictor of severe neutropenia in hyperthermic intraperitoneal therapy. Ann Surg Oncol. 2015;22 Suppl 3:873–9.CrossRef
11.
go back to reference Twohig KJ, Matthay RA. Pulmonary effects of cytotoxic agents other than bleomycin. Clin Chest Med. 1990;11(1):31–54.PubMed Twohig KJ, Matthay RA. Pulmonary effects of cytotoxic agents other than bleomycin. Clin Chest Med. 1990;11(1):31–54.PubMed
12.
go back to reference Saif MW, Dai T. Mitomycin-induced interstitial pneumonitis in a patient with BRCA2 associated metastatic pancreatic carcinoma. JOP. 2010;11(3):277–9.PubMed Saif MW, Dai T. Mitomycin-induced interstitial pneumonitis in a patient with BRCA2 associated metastatic pancreatic carcinoma. JOP. 2010;11(3):277–9.PubMed
13.
go back to reference Gonzalez-Moreno S, Lambert LA, Mansfield PF. Interstitial pneumonitis: an exceptional toxicity of hyperthermic intraperitoneal mitomycin C. Eur J Surg Oncol. 2008;34(4):482–4.CrossRefPubMed Gonzalez-Moreno S, Lambert LA, Mansfield PF. Interstitial pneumonitis: an exceptional toxicity of hyperthermic intraperitoneal mitomycin C. Eur J Surg Oncol. 2008;34(4):482–4.CrossRefPubMed
14.
go back to reference van Ruth S, Verwaal VJ, Zoetmulder FA. Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin N Am. 2003;12(3):771–80.CrossRefPubMed van Ruth S, Verwaal VJ, Zoetmulder FA. Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin N Am. 2003;12(3):771–80.CrossRefPubMed
15.
go back to reference Institute NC. Common terminology criteria for adverse events v4.0. NCI, NIH, DHHS. Institute NC. Common terminology criteria for adverse events v4.0. NCI, NIH, DHHS.
16.
go back to reference Orwoll ES, Kiessling PJ, Patterson JR. Interstitial pneumonia from mitomycin. Ann Intern Med. 1978;89(3):352–5.CrossRefPubMed Orwoll ES, Kiessling PJ, Patterson JR. Interstitial pneumonia from mitomycin. Ann Intern Med. 1978;89(3):352–5.CrossRefPubMed
17.
go back to reference Thompson CC, et al. Postoperative pulmonary toxicity associated with mitomycin-C therapy. South Med J. 1992;85(12):1257–9.CrossRefPubMed Thompson CC, et al. Postoperative pulmonary toxicity associated with mitomycin-C therapy. South Med J. 1992;85(12):1257–9.CrossRefPubMed
18.
go back to reference Verweij J, et al. Prospective study on the dose relationship of mitomycin C-induced interstitial pneumonitis. Cancer. 1987;60(4):756–61.CrossRefPubMed Verweij J, et al. Prospective study on the dose relationship of mitomycin C-induced interstitial pneumonitis. Cancer. 1987;60(4):756–61.CrossRefPubMed
Metadata
Title
Pulmonary toxicity after intraperitoneal mitomycin C: a case report of a rare complication of HIPEC
Authors
Melissa L. Abel
George Kokosis
Dan G. Blazer
Publication date
01-12-2017
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2017
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-016-1047-6

Other articles of this Issue 1/2017

World Journal of Surgical Oncology 1/2017 Go to the issue